Drug intelligence / Profile preview

eTIV_a

Development stage: Unknown
Lead developer: Novartis
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

eTIV_a is an egg-derived seasonal trivalent influenza vaccine that is thiomersal-free. Developed by Novartis, it is administered as a 0.5 mL single dose into the deltoid muscle. It has been evaluated in clinical trials for its safety and immunogenicity in adult and elderly subjects, both when administered alone and concomitantly with pneumococcal polysaccharide vaccine.

Other names: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free)

Beyond the preview

Go deeper on eTIV_a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eTIV_a.

Explore the full profile